Lidocaine and Ketamine Versus Standard Care on Acute and Chronic Pain
TerminatedNot applicableNCT00720330
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The investigators are conducting this study to find out if intravenous (injected through the vein) infusion of lidocaine and ketamine administered with general anesthesia is as effective as a paravertebral block in lessening pain after surgery and that both of these techniques are superior to general anesthesia alone in reducing pain immediately after surgery and in the long-term.
Study details
- Official title
- The Effect of Thoracolumbar Paravertebral Block or Intravenous Lidocaine and Ketamine Versus Standard Care on Acute and Chronic Pain After Inguinal Herniorrhaphy
- Conditions
- Pain
- Nausea
- Interventions
- Drug: ropivacaine
- Drug: Lidocaine/Ketamine
- Other: placebo
- Sponsor
- The Cleveland Clinic
- Start date
- 2008-07
- Primary completion
- 2010-02
- Sex
- Male
- Age range
- from 18 Years to 75 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age greater than 18 and less than 75 years * Male * Unilateral inguinal hernia scheduled for elective open repair Exclusion Criteria: * Incarcerated hernia or urgent procedure * Reoperation (recurrent hernia) * Contraindication to regional anesthesia such as: * Coagulopathy * Infection at the site of needle insertion * Pre-existing chronic pain (at any site) requiring treatment * Contraindication to any study medication (local anesthetic or ketamine) * History of significant Axis I psychiatric disease (major depressive disorder,bipolar disorder, schizophrenia, etc.) * Significant hepatic (ALT or AST \> 2 times normal) or renal (serum creatinine \> 2 mg/dl) impairment
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00720330